In Vivo Level of Poly(ADP-ribose)

Masanao Miwa, Chieri Ida, Sachiko Yamashita, Kenichi Kouyama, Yasuhito Kuroda, Takayuki Eguchi, Narumi Ohta, Teruaki Sato, Masataka Tsuda and Masakazu Tanaka
Additional contact information
Masanao Miwa: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Chieri Ida: Department of Applied Life Sciences, College of Nagoya Women’s University, Nagoya-shi, Aichi 467-8610, Japan
Sachiko Yamashita: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Kenichi Kouyama: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Yasuhito Kuroda: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Takayuki Eguchi: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Narumi Ohta: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Teruaki Sato: Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan
Masataka Tsuda: Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Hiroshima 739-0046, Japan
Masakazu Tanaka: Center for Chronic Viral Diseases, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima 890-8544, Japan

Challenges, 2018, vol. 9, issue 1, 1-15

Abstract: PolyADP-ribosylation is a post-translational modification that plays key roles in cellular physiological functions and DNA damage responses. PolyADP-ribosylation is finely and dynamically regulated by various enzymes and factors involved in the synthesis and degradation of poly(ADP-ribose) (PAR). To better understand the function of polyADP-ribosylation, it is necessary to quantify and monitor the change of the in vivo level of PAR, the product of polyADP-ribosylation, which is rapidly turning over and kept in quite low level in cells or in organs. Recent developments of potent inhibitors of polyADP-ribosylation is expected to kill BRCA1 / 2 -mutated breast cancer cells and ovarian cancer cells (synthetic lethality). To know the efficacy of these inhibitors in vivo, it is necessary to develop highly sensitive and reproducible methods to know PAR levels within cells or organs. However there have been several difficulties in measuring the physiologically low level of PAR without artefacts. Our experiments recently clarified that the method of sample preparation is very important in addition to the sensitivity and specificity. From reviewing the literature, including ours, we would like to emphasize the importance of the procedures of sample preparation for the assay, in addition to the sensitivity by comparing the reported PAR levels in vivo.

Keywords: polyADP-ribosylation; poly(ADP-ribose); PARP; PARG; PARP inhibitor; radioimmunoassay; ELISA; LC-MS/MS (search for similar items in EconPapers)
JEL-codes: A00 C00 Z00 (search for similar items in EconPapers)
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2078-1547/9/1/23/pdf (application/pdf)
https://www.mdpi.com/2078-1547/9/1/23/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jchals:v:9:y:2018:i:1:p:23-:d:148426

Access Statistics for this article

Challenges is currently edited by Ms. Karen Sun

More articles in Challenges from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().